Isomonat Retard (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle, which relaxes the vessels, lowers blood pressure, and decreases myocardial oxygen demand.

The specific dose and dosing schedule of Isomonat Retard are determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of isosorbide mononitrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Isomonat Retard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Isomonat Retard (isosorbide mononitrate) is a long‑acting organic nitrate, offering once‑daily dosing and steady plasma levels. Compared with short‑acting nitrates, it provides more consistent symptom control and fewer dosing fluctuations, while other classes such as beta‑blockers or calcium‑channel blockers act via different mechanisms.

Isomonat Retard should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Isomonat Retard is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescribing information states otherwise. Dosing time (e.g., morning) is guided by the prescriber to fit the patient’s routine.

Serious risks include severe hypotension, syncope, life‑threatening allergic reactions, methemoglobinemia, and rare cardiac events such as myocardial infarction or serious arrhythmias. Patients should seek immediate medical attention if they experience fainting, chest pain, or signs of an allergic reaction.

Isomonat Retard is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or other organic nitrates, those who have taken phosphodiesterase‑5 inhibitors within 24 hours, and individuals with severe hypotension or uncompensated heart failure unless specifically directed by a physician.